Friedemann JanusSenior VP, Head of Business Development & Licensing, Open Innovation and Divestitures at Bayer AG, Berlin, Germany
Dr. Friedemann Janus is Senior Vice President and Head of Regional Business Development & Licensing, Open Innovation and Divestitures for the Pharmaceuticals division of Bayer AG. He brings more than 20 years of experience across strategy, business development, licensing, divestments, commercial, and consulting.
In his current role, Friedemann is responsible for regional strategies that create ties to the local innovation ecosystems, access external innovation, identify and execute licensing opportunities and alliance management through the Bayer Collaborate to Cure Hubs in the US, EMEA, China, and Japan. Additionally, he is also responsible for all out licensing and divestiture activities for the Pharmaceutical division of Bayer.
Prior to taking on this role, Friedemann was Vice President & Global Head of Commercial and Global Head of Launch Management of the Xarelto product line driving the launch of Xarelto in its chronic indications.
Before joining Bayer, Friedemann was a Partner at McKinsey & Company, supporting Life Science companies in the US and Europe with focus on innovation and commercial strategies.
Friedemann holds a PhD in Molecular Biology from the Heinrich Pette Institute for Experimental Virology, in Hamburg University, Germany.